“Stem-cell therapy” describes different procedures, products, studies, and unsupported claims.
This guide organises the major clinical categories in China. It does not diagnose, recommend treatment, establish study eligibility, or turn research into paid care.
HB / STEM CELL / GUIDE
Status must be verified before disease or price
Established transplantation, an NMPA-approved product, registered research, and an unsupported commercial injection are not interchangeable. Exact cell identity, indication, hospital, protocol, oversight, risks, costs and follow-up must be documented.
PLAIN LANGUAGE
Medical terms in plain language
Hover, focus, or tap an underlined term for a short definition. These definitions do not replace the treating team’s explanation.
Disease-to-evidence search
Describe a disease or treatment question in ordinary words.
This local search finds relevant evidence pages. It does not diagnose, recommend a therapy, assess eligibility, or send your text to an external model.
Infusion reactions; infection and immune complications in a high-risk post-transplant population; uncertain long-term risks requiring continued observation
The approval does not extend to arthritis, diabetes, neurological disease, organ repair, autism, anti-ageing or wellness.
Individual clinical courses—reported, not promised.
These neutral summaries come from peer-reviewed case reports or provider-owned public reports. They are not testimonials, representative outcomes, comparative evidence, or a treatment recommendation.
Peer-reviewed case report5 Oct 2022
HSCT complication case: chronic hepatitis E
Case context
Very severe aplastic anaemia
Treatment reported
Matched-sibling allogeneic HSCT
Setting
China multi-institution case report
Observed course
Haematological remission was reported by day 22. Chronic hepatitis E later progressed to cirrhosis; six months of ribavirin was followed by viral clearance and improved liver findings.
Safety or complication
The report illustrates serious infection and liver complications during post-transplant immunosuppression.
Reported follow-up
Multi-year course; liver reassessment 461 days after antiviral initiation
Why this cannot be generalisedA complication case supporting surveillance, not a transplant efficacy estimate or a general infection-rate claim.
Autologous chemically induced pluripotent stem-cell-derived islets in a phase I study
Setting
Tianjin First Central Hospital
Observed course
The peer-reviewed preliminary report described insulin independence from day 75 and study endpoints met at one year.
Safety or complication
No transplant-related abnormality was identified at one-year review in the report.
Reported follow-up
One year
Why this cannot be generalisedOne first-in-human phase I participant; research only, not a marketed treatment or evidence of general safety and durability.
HarbourBridge did not treat, recruit, interview, or verify these individuals independently and has no relationship implied by inclusion.
COST / CONTROL
No defensible all-in stem-cell price range
Transplant cost depends on donor and graft route, conditioning, admission, infection, GVHD, intensive care, readmission and follow-up. A product price is not an episode price. Research participants must receive a written statement of study-related costs and injury arrangements; the applicable Chinese research rules prohibit charging participants research-related fees.